Our Cambridge-based US office
Novaliq Inc. is dedicated to leverage the advantages and the potential of the first and only water-free EyeSol® drug delivery technology and its innovative products in development in the U.S. It is a 100% subsidiary of Novaliq GmbH.
The Cambridge-based office is headed by Bernhard Günther, Novaliq’s founder and President of the Novaliq Inc.
Harvard Square One Mifflin Place Suite 400
Cambridge, MA 02138
As an emerging leader in the field of ophthalmology, two prescription drugs are in late stage clinical development:
1. Novaliq’s ESSENCE phase 2b/3 clinical trial (NCT 03292809) is a pivotal randomized, double-masked, vehicle-controlled, multi-center trial, designed to evaluate the safety, efficacy and tolerability of topical CyclASol® for the treatment of dry eye disease (DED). CyclASol®, has demonstrated better efficacy and tolerability versus current gold-standard RestasisTM in a US phase 2 trial.
2. Novaliq’s SEECASE clinical trial (NCT 03333057) is a phase 2, multi-center, randomized, double-masked, saline-controlled study to evaluate the effect of NOV03 at two different dosing regimens on the signs and symptoms of evaporative DED. NOV03 is potentially the first DED drug treatment addressing meibomian gland dysfunction (MGD) and evaporative-caused DED.